Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.035
Sell
RSI(14)
33.305
Neutral
STOCH(KDJ)(9,3,3)
25.966
Neutral
ATR(14)
0.084
Low Volatility
CCI(14)
-81.036
Neutral
Williams %R
89.600
Oversold
TRIX(12,20)
-1.610
Sell
StochRSI(14)
70.307
Sell
Search
Lexaria Bioscience Corp
LEXXAdd to Watchlist
0.592USD
-0.019-3.06%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
14.68MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Lexaria Bioscience Corp
Currency: USD Updated: 2026-05-15Key Insights
Lexaria Bioscience Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 94 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.75.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexaria Bioscience Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lexaria Bioscience Corp Highlights
StrengthsRisks
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 212.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 705.92K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.92K.
Overvalued
The company’s latest PE is -1.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.64M shares, decreasing 59.12% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 15.60K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.750
Target Price
+513.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Lexaria Bioscience Corp is 6.20, ranking 142 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 20.00K, representing a year-over-year decrease of 88.51%, while its net profit experienced a year-over-year decrease of 46.56%.
Score
Financials
6.75
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.78
Operational Efficiency
2.61
Growth Potential
6.61
Shareholder Returns
7.22
Lexaria Bioscience Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Lexaria Bioscience Corp is 6.63, ranking 115 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -1.24, which is -52.19% below the recent high of -0.59 and -646.96% above the recent low of -9.28.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 94/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Lexaria Bioscience Corp is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 6.00, with a high of 6.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.750
Target Price
+513.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Lexaria Bioscience Corp
LEXX
1
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Lexaria Bioscience Corp is 6.75, ranking 83 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.91 and the support level at 0.41, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.597
Sell
MA10
0.628
Sell
MA20
0.748
Sell
MA50
0.802
Sell
MA100
0.751
Sell
MA200
0.873
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Lexaria Bioscience Corp is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.61%, representing a quarter-over-quarter decrease of 22.09%. The largest institutional shareholder is James Simons, holding a total of 15.60K shares, representing 0.06% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lexaria Bioscience Corp is 1.53, ranking 148 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.35
VaR
+8.03%
240-Day Maximum Drawdown
+65.30%
240-Day Volatility
+117.06%
Return
Best Daily Return
60 days
+20.08%
120 days
+20.08%
5 years
+35.29%
Worst Daily Return
60 days
-21.93%
120 days
-33.58%
5 years
-33.58%
Sharpe Ratio
60 days
+0.01
120 days
-0.62
5 years
-0.08
Risk Assessment
Maximum Drawdown
240 days
+65.30%
3 years
+91.51%
5 years
+92.44%
Return-to-Drawdown Ratio
240 days
-0.60
3 years
-0.08
5 years
-0.20
Skewness
240 days
-0.53
3 years
+0.34
5 years
+0.27
Volatility
Realised Volatility
240 days
+117.06%
5 years
+110.53%
Standardised True Range
240 days
+14.78%
5 years
+33.12%
Downside Risk-Adjusted Return
120 days
-76.75%
240 days
-76.75%
Maximum Daily Upside Volatility
60 days
+72.15%
Maximum Daily Downside Volatility
60 days
+72.44%
Liquidity
Average Turnover Rate
60 days
+0.94%
120 days
+2.07%
5 years
--
Turnover Deviation
20 days
-27.24%
60 days
-36.15%
120 days
+41.06%
Peer Comparison
Pharmaceuticals
Lexaria Bioscience Corp
LEXX
5.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
